Neuland Laboratories Ltd banner

Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 12 004 INR -0.8% Market Closed
Market Cap: ₹154B

Net Margin

11.4%
Current
Declining
by 5.6%
vs 3-y average of 17%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.4%
=
Net Income
₹1.8B
/
Revenue
₹15.8B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.4%
=
Net Income
₹1.8B
/
Revenue
₹15.8B

Peer Comparison

Country Company Market Cap Net
Margin
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
154B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
856.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
566.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
243.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP
Loading...
US
Merck & Co Inc
NYSE:MRK
282.6B USD
Loading...
CH
Novartis AG
SIX:NOVN
222.2B CHF
Loading...
IE
Endo International PLC
LSE:0Y5F
237.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
153.4B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
115.7B USD
Loading...

Market Distribution

In line with most companies in India
Percentile
69th
Based on 5 531 companies
69th percentile
11.4%
Low
-305 007.7% — 2.1%
Typical Range
2.1% — 11.6%
High
11.6% — 1 221 633.3%
Distribution Statistics
India
Min -305 007.7%
30th Percentile 2.1%
Median 5.8%
70th Percentile 11.6%
Max 1 221 633.3%

Neuland Laboratories Ltd
Glance View

Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.

NEULANDLAB Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
11.4%
=
Net Income
₹1.8B
/
Revenue
₹15.8B
What is Neuland Laboratories Ltd's current Net Margin?

The current Net Margin for Neuland Laboratories Ltd is 11.4%, which is below its 3-year median of 17%.

How has Net Margin changed over time?

Over the last 3 years, Neuland Laboratories Ltd’s Net Margin has increased from 9.7% to 11.4%. During this period, it reached a low of 9.7% on Dec 31, 2022 and a high of 20.6% on Jun 30, 2024.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett